



Amino Acid PET – An Imaging Option to Identify Treatment Response, Posttherapeutic Effects, and Tumor Recurrence?

Norbert Galldiks^{1,2,3*} and Karl-Josef Langen^{2,4}

¹Department of Neurology, University of Cologne, Cologne, Germany, ²Institute of Neuroscience and Medicine, Forschungszentrum Jülich, Jülich, Germany, ³Center of Integrated Oncology (CIO), University of Cologne, Cologne, Germany, ⁴Department of Nuclear Medicine, University of Aachen, Aachen, Germany

OPEN ACCESS

Edited by:

Pamela Zyman New,
Montreal Neurological Institute
and Hospital, USA

Reviewed by:

Arjun Sahgal,
University of Toronto, Canada
Maria Caffo,
University of Messina, Italy

*Correspondence:

Norbert Galldiks
n.galldiks@fz-juelich.de

Specialty section:

This article was submitted
to Neuro-Oncology,
a section of the journal
Frontiers in Neurology

Received: 11 March 2016

Accepted: 18 July 2016

Published: 28 July 2016

Citation:

Galldiks N and Langen K-J (2016)
Amino Acid PET – An Imaging
Option to Identify Treatment
Response, Posttherapeutic
Effects, and Tumor Recurrence?
Front. Neurol. 7:120.
doi: 10.3389/fneur.2016.00120

Routine diagnostics and treatment monitoring in patients with primary and secondary brain tumors is usually based on contrast-enhanced standard MRI. However, the capacity of standard MRI to differentiate neoplastic tissue from non-specific posttreatment effects may be limited particularly after therapeutic interventions such as radio- and/or chemotherapy or newer treatment options, e.g., immune therapy. Metabolic imaging using PET may provide relevant additional information on tumor metabolism, which allows a more accurate diagnosis especially in clinically equivocal situations, particularly when radiolabeled amino acids are used. Amino acid PET allows a sensitive monitoring of a response to various treatment options, the early detection of tumor recurrence, and an improved differentiation of tumor recurrence from posttherapeutic effects. In the past, this method had only limited availability due to the use of PET tracers with a short half-life, e.g., C-11. In recent years, however, novel amino acid PET tracers labeled with positron emitters with a longer half-life (F-18) have been developed and clinically validated, which allow a more efficient and cost-effective application. These developments and the well-documented diagnostic performance of PET using radiolabeled amino acids suggest that its application continues to spread and that this technique may be available as a routine diagnostic tool for several indications in the field of neuro-oncology.

Keywords: FET PET, MET PET, FDOPA PET, radiolabeled amino acids, pseudoprogression, pseudoresponse, radiation necrosis

INTRODUCTION

To date, structural MRI is the most important diagnostic tool in patients with brain tumors (1). Since decades, changes in contrast enhancement extent on MRI are used as an indicator of response to a certain therapy or tumor relapse (2, 3), although the reliability in distinguishing tumor tissue from treatment effects such as a blood–brain barrier breakdown is limited (4). For instance, reactive transient blood–brain barrier alterations with consecutive contrast enhancement – typically after radiotherapy with or without concomitant temozolomide – can mimic tumor progression and occur very early within the first 12 weeks after radiotherapy and is called pseudoprogression. Clinically, pseudoprogression is of substantial importance in neuro-oncology and occurs approximately in 10–30% of patients with malignant glioma (5–7). Other important side effects

of radiotherapy are radiation-induced changes with late onset, particularly radiation necrosis, which usually manifests several months or even years later than pseudoprogression (8). Furthermore, transient blood–brain barrier breakdown may also result from cerebral ischemia, postoperative inflammation, or epileptic seizures.

After the approval of antiangiogenic drugs (e.g., bevacizumab), the so-called phenomenon “pseudoresponse” has been described, which may complicate the assessment of treatment response by evaluating changes in contrast enhancement according to the Macdonald criteria only (3). Within a few weeks after the initiation of treatment, it has been observed that antiangiogenic drugs, such as bevacizumab, are able to markedly reduce contrast enhancement (9), producing response rates consistent with partial or even complete responses. Some of these partial or complete responses observed on MR images may result from a quick normalization of abnormally permeable blood vessels, indicating – at least in part – a restoration of the blood–brain barrier integrity. Thus, a decrease in contrast enhancement, which indicates a response on MRI, may not reflect true anti-tumoral effects of antiangiogenic drugs (10). Furthermore, following antiangiogenic treatment, MRI suggests, not infrequently, an impressive radiological response, which can be in clear contrast to the clinical benefit caused by antiangiogenic therapy effects. Hence, the use of antiangiogenic drugs, most probably, affects the image findings of enhancing tumor portions considerably, more effectively than that of non-enhancing parts of the tumor (10). In order to overcome the limitations of the assessment of tumor response to antiangiogenic treatment by evaluation of changes in contrast enhancement only (according to the Macdonald criteria), the Response Assessment in Neuro-Oncology (RANO) group suggested new recommendations for evaluating response (2). Particularly, for antiangiogenic drugs, FLAIR or T2 signal hyperintensity was recommended as a surrogate marker for non-enhancing tumor to help determine tumor progression, and thereby include non-enhancing FLAIR or T2 signal alterations as criteria for determining tumor response or progression (“non-enhancing tumor progression”) (2).

However, present RANO criteria do not provide quantitative values of FLAIR or T2 signal change for the diagnosis of tumor progression. Various differential diagnoses, such as tumor-related edema, radiation injury, demyelination, ischemia, and infection, can result in a hyperintense FLAIR or T2 signal alteration, which is difficult to distinguish from non-enhancing tumor (10). Consequently, alternative diagnostic methods are necessary to improve the identification of treatment response, posttherapeutic effects, and tumor recurrence.

TREATMENT RESPONSE

The feasibility and usefulness of amino acid PET using the tracers ^{11}C -methyl-L-methionine (MET), O -(2- ^{18}F fluoroethyl)-L-tyrosine (FET), and 3,4-dihydroxy-6- ^{18}F -fluoro-L-phenylalanine (FDOPA) for treatment assessment after radiochemotherapy, stereotactic brachytherapy, alkylating chemotherapy, and antiangiogenic therapy using bevacizumab and other experimental approaches have been demonstrated in several studies and case series. The

currently available PET data regarding these tracers suggest that both a reduction of amino acid uptake and a decrease of the metabolically active tumor volume of a glioma are a sign of response to treatment.

Radiotherapy

A prospective study evaluated the prognostic value of early changes of FET uptake after postoperative radiochemotherapy in patients with glioblastoma (11, 12). It could be observed that PET responders with a reduction of the maximal tumor/brain ratio at least of more than 10% had a significantly longer progression-free and overall survival than patients with stable or increasing tracer uptake after radiochemotherapy. Regarding stereotactic brachytherapy using iodine-125 seeds, both tumor/brain ratios and metabolically active tumor volumes as determined by FET PET were able to differentiate between late posttherapeutic effects after 6 months or later and local tumor progression with high diagnostic accuracy (13).

Alkylating Chemotherapy

A reliable monitoring of alkylating chemotherapy, i.e., temozolomide and nitrosoureas such as lomustine, could be observed with MET PET in recurrent or progressive high-grade glioma patients (14–16) and both with FET and MET PET in patients with recurrent or progressive low-grade glioma (17–19). Particularly, response to treatment in low-grade gliomas was associated with an earlier reduction of the FET PET tumor volume when compared to FLAIR/T2 signal changes.

Antiangiogenic Therapy

More recent studies suggest that especially the decrease of the metabolically active tumor volume as assessed by amino acid PET using the tracers FET and FDOPA is useful to assess antiangiogenic therapy failure of bevacizumab earlier than MRI according to RANO criteria and, moreover, to identify responders to bevacizumab with favorable outcome (20–23).

In a series of 11 patients, FET PET detected failure of antiangiogenic therapy in 4 patients earlier than standard MRI (22). Similar results were observed in another study including 10 patients (21). In this study, treatment response based on RANO criteria was discordant in four patients to FET PET findings, indicating pseudoresponse on MRI. Furthermore, FET PET was able to detect tumor progression earlier than MRI (median time benefit, 10.5 weeks). In these FET PET studies (21, 22), a favorable outcome of responders to bevacizumab was observed when a decrease of the metabolically active tumor volume of 45% or more was present. Furthermore, a cost-effectiveness analysis suggests that the additional use of FET PET in the management of patients with recurrent high-grade glioma treated with bevacizumab may be cost-effective (24).

Using FDOPA PET, a recent study including 30 patients reported that responders based on FDOPA PET data survived 3.5 times longer than non-responders. In contrast, responders based on RANO criteria lived only 1.5 times longer than non-responders (20). Furthermore, this study also demonstrated that changes in the metabolically active tumor volume were highly prognostic. The absolute metabolically active tumor volume at

the first follow-up scan (threshold, 18 ml) provided the strongest prediction of progression-free and overall survival (20).

Other Treatment Options

In various experimental treatment options such as intracavitary radioimmunotherapy, convection-enhanced delivery of paclitaxel, and adjuvant maintenance therapy with imatinib in combination with hydroxyurea (25–27) treatment effects could be successfully monitored by PET using MET and FET.

POSTTHERAPEUTIC EFFECTS AND TUMOR RECURRENCE

After neuro-oncological treatment, particularly, non-neoplastic increase in contrast enhancement (**Figure 1**) or a newly diagnosed contrast-enhancing lesion on standard MRI have been found, which may considerably confuse patient management in neuro-oncology because posttherapeutic effects cannot be always ruled out. In this setting, the value of amino acid PET using the tracers MET, FET, and FDOPA for the identification of tumor recurrence or progression in patients with low-grade and high-grade glioma has been described in many studies (28–35). Overall, a higher diagnostic performance compared to standard MRI has been observed. However, in many of these

studies, early delayed posttherapeutic effects were not further specified from late effects.

Pseudoprogression

After the implementation of chemoradiation with concurrent temozolomide for glioblastoma patients representing the current standard of care, there has been an increasing awareness of progressive contrast-enhancing lesions on conventional MRI, which are not related to a true disease progression, but which are most probably due to a treatment effect and are called pseudoprogression. This phenomenon occurs usually within the first 12 weeks after chemoradiation with concurrent temozolomide or radiotherapy alone (2, 5, 36), and this time, frame has been implemented into the RANO criteria (2). If histology is not available, pseudoprogression is usually retrospectively diagnosed and is based on increasing contrast enhancement on MRI suggesting tumor progression that eventually remains stable or even regresses during further follow-up MRI imaging without any change in treatment (37) (**Figure 2**). However, cases with a later onset of pseudoprogression have been observed, particularly after chemoradiation, using temozolomide in combination with nitrosoureas such as lomustine (CCNU) (38, 39). In high-grade glioma patients, the rate of pseudoprogression seems to be between 10 and 30% (5–7) and is clinically of great importance because an




FIGURE 1 | Example of a 31-year-old patient with an anaplastic astrocytoma in the left parahippocampal region with posttherapeutic effects.

Previous treatment consisted brachytherapy and external fractionated radiotherapy with concomitant and adjuvant temozolomide. Brain imaging with standard MRI and FET PET at recurrence/before initiation of chemotherapy (left column) and 4 months later after two cycles of lomustine chemotherapy (right column). Enlargement of contrast enhancement and the T2 signal is suggesting tumor progression, whereas FET PET indicates a reduction of metabolic activity.




FIGURE 2 | FET PET and conventional MR imaging in a 47-year-old patient prior to histological confirmation of glioblastoma diagnosis (left column), and 8 weeks (middle column) and 3 months after completion of radiochemotherapy with temozolomide (right column). The follow-up MR images 8 weeks after completion of radiochemotherapy suggests markedly tumor progression (middle column). In contrast, the FET PET image shows decreased metabolic activity compared to initial FET PET (maximum tumor/brain ratio 3.3 vs. 4.7) indicating pseudoprogression. Correspondingly, follow-up MRI, 3 months after radiochemotherapy, shows an improvement with regressive findings without change in the treatment regimen (right column).

effective therapy might be erroneously terminated, potentially and negatively impacting the outcome.

Unfortunately, standard MR imaging does not allow a reliable differentiation of tumor relapse from pseudoprogression. Several studies have suggested that, within a narrow time frame of 12 weeks after completion of radiochemotherapy, FET PET might be helpful for this distinction (11, 40, 41). Subsequently, in a larger patient cohort with glioblastomas ($n = 22$), the diagnostic accuracy for FET PET of more than 90% for differentiating pseudoprogression from true tumor progression after chemoradiation with concurrent temozolomide has been observed (42). In line with this study, FDOPA PET may also be useful for diagnosing patients with pseudoprogression. A study with glioblastoma patients ($n = 110$) revealed an accuracy of 82% for FDOPA PET for the correct diagnosis of true tumor progression or recurrence (32). However, in this study, early and late delayed treatment-induced changes, such as pseudoprogression or radiation necrosis, were not further specified. Thus, despite the lack of subsequent PET studies with a higher number of patients evaluating this particular time window of 12 weeks after chemoradiation, the present data on amino acid PET suggest that this technique is helpful for the diagnosis of pseudoprogression following chemoradiation of glioblastoma.

Radiation Necrosis

This phenomenon is an important side effect of radiotherapy and belongs to radiation-induced changes with late onset and usually manifests several months or even years later than pseudoprogression (8). A radiation necrosis may occur after radiotherapy of a glioma as well as brain metastasis.

In view of both the sociodemographic changes with an increasing elderly population and a wider spectrum of treatment options for extracranial tumors resulting in an improvement of outcome, an increasing number of patients diagnosed with brain metastasis can be expected (43, 44). Besides neurosurgical resection, radiotherapy options, such as brachytherapy, radiosurgery, and whole-brain radiation therapy, are frequently used to treat patients with brain metastasis. In this group of patients, neuro-oncologists are often confronted with the clinical problem that after radiation therapy, and, in particular, after radiosurgery, standard MRI cannot reliably differentiate brain metastasis recurrence or progression from radiation necrosis.

Following radiosurgery in brain metastasis patients, a considerable rate of radiation necrosis (24% of 310 cerebral metastases) has been reported (45). Depending on the irradiated volume receiving a critical radiation dose, the risk of radiation necrosis may increase up to 47% (45). Moreover, some studies in patients

with primary brain tumors suggest that radiation necrosis occurs in approximately 5–25% of patients receiving standard radiotherapy (4, 46).

In order to address this highly relevant clinical problem, amino acid PET has been recently used. For instance, simple semiquantitative regions-of-interest (ROI) analyses were used in MET PET studies for the calculation of tumor-to-brain ratios and revealed a sensitivity and specificity of 70–80% for the differentiation of local brain metastasis recurrence from radiation-related effects (47, 48). Similarly, a FDOPA PET study revealed a sensitivity and specificity of more than 80% (49). Another study has compared the diagnostic performance of FDOPA PET with that of perfusion-weighted MRI (PWI) in patients with brain metastases after stereotactic radiosurgery. In this study, the accuracy of FDOPA PET was 91% and superior to PWI metrics, which yielded an accuracy of 76% (50). In line with this, a similar diagnostic performance has also been observed for FET PET: using tumor/brain ratios in combination with the evaluation of time-activity curves derived from kinetic FET PET scans, a sensitivity and specificity of about 90% could be observed (51).

CONCLUSION AND PERSPECTIVES

In summary, the use of amino acid PET imaging is helpful to provide an early assessment of therapy efficacy and for the differentiation of posttherapeutic effects from tumor recurrence. This technique aids oncologists to optimize therapeutic management of brain tumors and has the potential to evaluate response to newer treatment options such as immune or targeted therapy.

Regarding the tracer selection it has to be considered that, in comparison to MET labeled with C-11 (half-life, 20 min), the main advantage of FET is the longer half-life of the F-18 label (110 min), which allows a widespread clinical distribution. In addition, FET uptake appears to be more specific for neoplastic tissue, because there is a higher uptake of MET in inflammatory cells and tissues. The lower specificity of MET may be explained by its higher affinity for macrophages compared with FET as demonstrated in animal experiments (52). Of great interest is the presence of differential FET uptake kinetics in malignant gliomas and low-grade gliomas, which have not been observed in other amino acid tracers (53, 54), and the lack of physiological uptake in the basal ganglia when compared with FDOPA PET (44). Hence, FET seems to be the most promising amino acid tracer for PET imaging in brain tumor patients and should be considered for prospective studies (55).

It has to be noted that amino acid PET tracers eventually may show uptake in non-tumoral brain lesions. In contrast to MET, experiments in animal models have shown that FET exhibits no uptake in inflammatory lymph nodes and in inflammatory cells. However, false positive tracer uptake has been observed for MET

as well as for FET in patients with brain abscesses, demyelinating processes, hematomas, cerebral ischemia, or in cases with pronounced radionecrosis (56–58). Additionally, in glioma patients with seizure clusters or status epilepticus, a transient FET uptake in cortical brain areas has been observed, which were not affected by tumor tissue (44). Therefore, increased uptake of the tracers is not thoroughly specific for cerebral gliomas although increased amino acid uptake has a high positive predictive value for cerebral gliomas (59). In clinical practice, false positive uptake in non-tumoral lesions is rare (30, 42, 60) and usually mild, thus affecting the diagnostic performance of amino acid PET imaging insignificantly.

Furthermore, the diagnostic performance of amino acid PET needs to be compared with advanced MRI techniques, e.g., diffusion- and perfusion-weighted imaging, sodium MRI, and chemical exchange saturation transfer (CEST) imaging. There is evidence that these methods may be helpful to differentiate tumor relapse from posttherapeutic effects (61–63). In order to provide the optimal diagnostic work-up to the individual patients, multimodal imaging studies should be on the basis of reader-independent image evaluation. From these imaging studies, surrogate parameters need to be derived, which can then be used in clinical routine.

In order to identify these surrogate imaging markers, the use of hybrid PET/MR imaging technology may be helpful. This technique allows the simultaneous acquisition of valuable diagnostic information. For example, recent studies support the acquisition of dynamic FET PET, standard anatomical MRI sequences, and PWI MRI in a single session (“one-stop-shop”) on a hybrid PET/MR scanner in glioma patients (64, 65). Moreover, this technology helps to minimize the patients’ discomfort (e.g., considerable reduction of scanning time, only a single transport to the imaging facility, avoidance of sedation or anesthesia, particularly in children) and helps to optimize co-registration of various imaging modalities. However, the MRI-based attenuation correction can be very challenging.

As we move forward with new technologies and innovations in neuroimaging, the challenge of determining pseudoprogression from true tumor progression may be resolved. Combining the efforts and knowledge of interested researchers in this way will hasten the solution to this problem.

ETHICS STATEMENT

The local ethics committee approved the evaluation of retrospectively collected patient data. All patients gave written-informed consent prior to each PET investigation.

AUTHOR CONTRIBUTIONS

NG: writing of the manuscript. K-JL: review of the manuscript.

REFERENCES

1. DeAngelis LM. Brain tumors. *N Engl J Med* (2001) 344:114–23. doi:10.1056/NEJM200101113440207
2. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. *J Clin Oncol* (2010) 28(11):1963–72. doi:10.1200/JCO.2009.26.3541

3. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. *J Clin Oncol* (1990) 8(7):1277–80.
4. Kumar AJ, Leeds NE, Fuller GN, Van Tassel P, Maor MH, Sawaya RE, et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. *Radiology* (2000) 217(2):377–84. doi:10.1148/radiology.217.2.r00nv36377
5. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. *Lancet Oncol* (2008) 9(5):453–61. doi:10.1016/S1470-2045(08)70125-6
6. Young RJ, Gupta A, Shah AD, Graber JJ, Zhang Z, Shi W, et al. Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. *Neurology* (2011) 76(22):1918–24. doi:10.1212/WNL.0b013e31821d74e7
7. Radvbruch A, Fladt J, Kickingereder P, Wiestler B, Nowosielski M, Baumer P, et al. Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence. *Neuro Oncol* (2015) 17(1):151–9. doi:10.1093/neuonc/nou129
8. Shah AH, Snelling B, Bregy A, Patel PR, Tememe D, Bhatia R, et al. Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality? *J Neurooncol* (2013) 112(2):141–52. doi:10.1007/s11060-013-1059-9
9. Vredenburgh JJ, Desjardins A, Herndon JE II, Marcello J, Reardon DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. *J Clin Oncol* (2007) 25(30):4722–9. doi:10.1200/JCO.2007.12.2440
10. Ahluwalia MS, Wen PY. Antiangiogenic therapy for patients with glioblastoma: current challenges in imaging and future directions. *Expert Rev Anticancer Ther* (2011) 11(5):653–6. doi:10.1586/era.11.35
11. Galldiks N, Langen K, Holy R, Pinkawa M, Stoffels G, Nolte K, et al. Assessment of treatment response in patients with glioblastoma using [18F]fluoroethyl-L-tyrosine PET in comparison to MRI. *J Nucl Med* (2012) 53(7):1048–57. doi:10.2967/jnumed.111.098590
12. Piroth MD, Pinkawa M, Holy R, Klotz J, Nussen S, Stoffels G, et al. Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme. *Int J Radiat Oncol Biol Phys* (2011) 80(1):176–84. doi:10.1016/j.ijrobp.2010.01.055
13. Jansen NL, Suchorska B, Schwarz SB, Eigenbrod S, Lutz J, Graute V, et al. [18F] fluoroethyltyrosine-positron emission tomography-based therapy monitoring after stereotactic iodine-125 brachytherapy in patients with recurrent high-grade glioma. *Mol Imaging* (2013) 12(3):137–47. doi:10.2310/7290.2012.00027
14. Galldiks N, Kracht LW, Burghaus L, Thomas A, Jacobs AH, Heiss WD, et al. Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. *Eur J Nucl Med Mol Imaging* (2006) 33(5):516–24. doi:10.1007/s00259-005-0002-5
15. Galldiks N, Kracht LW, Burghaus L, Ullrich RT, Backes H, Brunn A, et al. Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma. *Mol Imaging* (2010) 9(1):40–6. doi:10.2310/7290.2010.00002
16. Herholz K, Kracht LW, Heiss WD. Monitoring the effect of chemotherapy in a mixed glioma by C-11-methionine PET. *J Neuroimaging* (2003) 13(3):269–71. doi:10.1111/j.1552-6569.2003.tb00190.x
17. Roelcke U, Wyss MT, Nowosielski M, Ruda R, Roth P, Hofer S, et al. Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas. *Neuro Oncol* (2016) 18(5):744–51. doi:10.1093/neuonc/nov282
18. Wyss M, Hofer S, Bruehlmeier M, Hefti M, Uhlmann C, Bartschi E, et al. Early metabolic responses in temozolomide treated low-grade glioma patients. *J Neurooncol* (2009) 95(1):87–93. doi:10.1007/s11060-009-9896-2
19. Tang BN, Sadeghi N, Branle F, De Witte O, Wikler D, Goldman S. Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma. *J Neurooncol* (2005) 71:161–8. doi:10.1007/s11060-004-9654-4
20. Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Grogan T, et al. Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy. *Clin Cancer Res* (2014) 20(13):3550–9. doi:10.1158/1078-0432.CCR-13-1440
21. Galldiks N, Rapp M, Stoffels G, Fink GR, Shah NJ, Coenen HH, et al. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]fluoroethyl-L-tyrosine PET in comparison to MRI. *Eur J Nucl Med Mol Imaging* (2013) 40(1):22–33. doi:10.1007/s00259-012-2251-4
22. Hutterer M, Nowosielski M, Putzer D, Waitz D, Tinkhauser G, Kostron H, et al. O-(2-[18F]-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. *J Nucl Med* (2011) 52(6):856–64. doi:10.2967/jnumed.110.086645
23. Harris RJ, Cloughesy TF, Pope WB, Nghiemphu PL, Lai A, Zaw T, et al. 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. *Neuro Oncol* (2012) 14(8):1079–89. doi:10.1093/neuonc/nos141
24. Heinzel A, Müller D, Langen KJ, Blaum M, Verburg FA, Mottaghy FM, et al. The use of O-(2-[18F]-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis. *J Nucl Med* (2013) 54:1217–22. doi:10.2967/jnumed.113.120089
25. Pöppel G, Goldbrunner R, Gildehaus FJ, Kreth FW, Tanner P, Holtmannspotter M, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. *Eur J Nucl Med Mol Imaging* (2005) 32:1018–25. doi:10.1007/s00259-005-1819-7
26. Pöppel G, Götz C, Rachinger W, Schnell O, Gildehaus FJ, Tonn JC, et al. Serial O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. *Eur J Nucl Med Mol Imaging* (2006) 33:792–800. doi:10.1007/s00259-005-0053-7
27. Galldiks N, Ullrich R, Schroeter M, Fink GR, Kracht LW. Imaging biological activity of a glioblastoma treated with an individual patient-tailored, experimental therapy regimen. *J Neurooncol* (2009) 93:425–30. doi:10.1007/s11060-008-9790-3
28. Mehrkens JH, Pöppel G, Rachinger W, Herms J, Seelos K, Tatsch K, et al. The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment. *J Neurooncol* (2008) 88(1):27–35. doi:10.1007/s11060-008-9526-4
29. Pöppel G, Götz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K. Value of O-(2-[18F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. *Eur J Nucl Med Mol Imaging* (2004) 31(11):1464–70. doi:10.1007/s00259-004-1590-1
30. Rachinger W, Goetz C, Pöppel G, Gildehaus FJ, Kreth FW, Holtmannspotter M, et al. Positron emission tomography with O-(2-[18F] fluoroethyl)-L-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. *Neurosurgery* (2005) 57(3):505–11. doi:10.1227/01.NEU.0000171642.49553.B0
31. Galldiks N, Stoffels G, Filss C, Rapp M, Blau T, Tscherpel C, et al. The use of dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. *Neuro Oncol* (2015) 17(9):1293–300. doi:10.1093/neuonc/nov088
32. Herrmann K, Czernin J, Cloughesy T, Lai A, Pomykala KL, Benz MR, et al. Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients. *Neuro Oncol* (2014) 16(4):603–9. doi:10.1093/neuonc/not166
33. Van Laere K, Ceyssens S, Van Calenbergh F, de Groot T, Menten J, Flamen P, et al. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. *Eur J Nucl Med Mol Imaging* (2005) 32(1):39–51. doi:10.1007/s00259-004-1564-3
34. Ullrich RT, Kracht L, Brunn A, Herholz K, Frommolt P, Miletic H, et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. *J Nucl Med* (2009) 50:1962–8. doi:10.2967/jnumed.109.065904
35. Galldiks N, Stoffels G, Ruge MI, Rapp M, Sabel M, Reifenberger G, et al. Role of O-(2-[18F]-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma. *J Nucl Med* (2013) 54(12):2046–54. doi:10.2967/jnumed.113.123836
36. Brandsma D, van den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. *Curr Opin Neurol* (2009) 22(6):633–8. doi:10.1097/WCO.0b013e328332363e
37. Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, Smitt PA, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoradiation with temozolomide. *Cancer* (2008) 113(2):405–10. doi:10.1002/cncr.23562

38. Stuplich M, Hadizadeh DR, Kuchelmeister K, Scorzin J, Filss C, Langen KJ, et al. Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide. *J Clin Oncol* (2012) 30(21):e180–3. doi:10.1200/JCO.2011.40.9565
39. Kebir S, Fimmers R, Galldiks N, Schaefer N, Mack F, Schaub C, et al. Late pseudoprogression in glioblastoma: diagnostic value of dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET. *Clin Cancer Res* (2016) 22(9):2190–6. doi:10.1158/1078-0432.CCR-15-1334
40. Piroth MD, Pinkawa M, Holy R, Klotz J, Schaar S, Stoffels G, et al. Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. Results of a prospective phase II study. *Strahlenther Onkol* (2012) 188(4):334–9. doi:10.1007/s00066-011-0060-5
41. Grosu AL, Astner ST, Riedel E, Nieder C, Wiedenmann N, Heinemann F, et al. An interindividual comparison of O-(2-[(18F)fluoroethyl]-L-tyrosine (FET)- and L-[methyl-(11C)]methionine (MET)-PET in patients with brain gliomas and metastases. *Int J Radiat Oncol Biol Phys* (2011) 81(4):1049–58. doi:10.1016/j.ijrobp.2010.07.002
42. Galldiks N, Dunkl V, Stoffels G, Hutterer M, Rapp M, Sabel M, et al. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[(18F)fluoroethyl]-L-tyrosine PET. *Eur J Nucl Med Mol Imaging* (2015) 42(5):685–95. doi:10.1007/s00259-014-2959-4
43. Kickingereder P, Dorn F, Blau T, Schmidt M, Kocher M, Galldiks N, et al. Differentiation of local tumor recurrence from radiation-induced changes after stereotactic radiosurgery for treatment of brain metastasis: case report and review of the literature. *Radiat Oncol* (2013) 6(8):52. doi:10.1186/1748-717X-8-52
44. Hutterer M, Krenn Y, Kunz A, McCoy M, Egger B, Schröder M, et al. Increased cerebral amino acid uptake during and after epileptic disorders mimics brain tumor in 18F-FET PET. *Neuro Oncol* (2014) 16(Suppl 5):v146. doi:10.1093/neuonc/nou264.35
45. Minniti G, Clarke E, Lanzetta G, Osti MF, Trasimeni G, Bozzao A, et al. Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. *Radiat Oncol* (2011) 15(6):48. doi:10.1186/1748-717X-6-48
46. Marks JE, Baglan RJ, Prasad SC, Blank WF. Cerebral radionecrosis: incidence and risk in relation to dose, time, fractionation and volume. *Int J Radiat Oncol Biol Phys* (1981) 7:243–52. doi:10.1016/0360-3016(81)90443-0
47. Terakawa Y, Tsuyuguchi N, Iwai Y, Yamanaka K, Higashiyama S, Takami T, et al. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. *J Nucl Med* (2008) 49(5):694–9. doi:10.2967/jnumed.107.048082
48. Tsuyuguchi N, Sunada I, Iwai Y, Yamanaka K, Tanaka K, Takami T, et al. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? *J Neurosurg* (2003) 98(5):1056–64. doi:10.3171/jns.2003.98.5.1056
49. Lizarraga KJ, Allen-Auerbach M, Czernin J, DeSalles AA, Yong WH, Phelps ME, et al. (18F)-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment. *J Nucl Med* (2014) 55(1):30–6. doi:10.2967/jnumed.113.121418
50. Ciccone F, Minniti G, Romano A, Papa A, Scaringi C, Tavanti F, et al. Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery. *Eur J Nucl Med Mol Imaging* (2015) 42(1):103–11. doi:10.1007/s00259-014-2886-4
51. Galldiks N, Stoffels G, Filss CP, Piroth MD, Sabel M, Ruge MI, et al. Role of O-(2-18F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis. *J Nucl Med* (2012) 53(9):1367–74. doi:10.2967/jnumed.112.103325
52. Salber D, Stoffels G, Pauleit D, Oros-Peusquens AM, Shah NJ, Klauth P, et al. Differential uptake of O-(2-18F-fluoroethyl)-L-tyrosine, L-3H-methionine, and 3H-deoxyglucose in brain abscesses. *J Nucl Med* (2007) 48:2056–62. doi:10.2967/jnumed.107.046615
53. Moulin-Romsée G, D'Hondt E, de Groot T, Goffin J, Sciot R, Mortelmans L, et al. Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11C-methionine? *Eur J Nucl Med Mol Imaging* (2007) 34(12):2082–7. doi:10.1007/s00259-007-0557-4
54. Kratochwil C, Combs SE, Leotta K, Afshar-Oromieh A, Rieken S, Debus J, et al. Intra-individual comparison of (18F)-FET and (18F)-DOPA in PET imaging of recurrent brain tumors. *Neuro Oncol* (2014) 16(3):434–40. doi:10.1093/neuonc/not199
55. Galldiks N, Langen KJ, Pope WB. From the clinician's point of view – what is the status quo of positron emission tomography in patients with brain tumors? *Neuro Oncol* (2015) 17(11):1434–44. doi:10.1093/neuonc/nov118
56. Singhal T, Narayanan TK, Jain V, Mukherjee J, Mantil J. 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. *Mol Imaging Biol* (2008) 10:1–18. doi:10.1007/s11307-007-0115-2
57. Hutterer M, Nowosielski M, Putzer D, Jansen NL, Seiz M, Schocke M, et al. [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. *Neuro Oncol* (2013) 15(3):341–51. doi:10.1093/neuonc/not081
58. Hutterer M, Galldiks N, Hau P, Langen KJ. Pitfalls of [18F]-FET PET in the diagnostics of brain tumors. *Der Nuklearmediziner* (2015) 38(4):293–303. doi:10.1055/s-0035-1564177
59. Pichler R, Dunzinger A, Wurm G, Pichler J, Weis S, Nussbaumer K, et al. Is there a place for FET PET in the initial evaluation of brain lesions with unknown significance? *Eur J Nucl Med Mol Imaging* (2010) 37:1521–8. doi:10.1007/s00259-010-1457-6
60. Popperl G, Gotz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K. Value of O-(2-[18F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. *Eur J Nucl Med Mol Imaging* (2004) 31(11):1464–70. doi:10.1007/s00259-004-1590-1
61. Cha J, Kim ST, Kim HJ, Kim BJ, Kim YK, Lee JY, et al. Differentiation of tumor progression from pseudoprogression in patients with posttreatment glioblastoma using multiparametric histogram analysis. *AJNR Am J Neuroradiol* (2014) 35(7):1309–17. doi:10.3174/ajnr.A3876
62. Kong DS, Kim ST, Kim EH, Lim DH, Kim WS, Suh YL, et al. Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status. *AJNR Am J Neuroradiol* (2011) 32:382–7. doi:10.3174/ajnr.A2286
63. Mangla R, Singh G, Ziegler D, Milano MT, Korones DN, Zhong J, et al. Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. *Radiology* (2010) 256:575–84. doi:10.1148/radiol.10091440
64. Filss CP, Galldiks N, Stoffels G, Sabel M, Wittsack HJ, Turowski B, et al. Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors. *J Nucl Med* (2014) 55(4):540–5. doi:10.2967/jnumed.113.129007
65. Henriksen OM, Larsen VA, Muhic A, Hansen AE, Larsson HB, Poulsen HS, et al. Simultaneous evaluation of brain tumour metabolism, structure and blood volume using [(18F)-fluoroethyltyrosine (FET) PET/MRI: feasibility, agreement and initial experience. *Eur J Nucl Med Mol Imaging* (2016) 43(1):103–12. doi:10.1007/s00259-015-3183-6

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Galldiks and Langen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.